# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN-TD
- Date: 1947-06-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review: OCD treatment, buprenorphine, pain and the audiogram. **S**

## History of present illness

Mr. Hughes returns four weeks after starting buprenorphine and sertraline. Withdrawal settled on the second day of buprenorphine, and on 8 mg twice daily he has no cravings and has taken no other opioid; his bowels are a little slow, and he is drinking more water. He has had four exposure sessions: he now touches door handles and his desk without washing at once, and he lets himself wash for two minutes rather than ten. Washing and checking take about three hours a day. His assistant has attended one session. He has had no side effects from sertraline; no one from the clinic called two weeks after he started it. Physical therapy twice weekly has eased his shoulder. He eats two meals a day. He could not bring himself to use the clinic bathroom today, so no urine test has been done since intake. The audiogram was done this morning. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 8 mg twice daily; no cravings; no other opioid use |
| Rituals | About three hours a day; Y-BOCS 24 |
| Sertraline | 50 mg for four weeks; no side effects |
| Pain | PEG 5.7 |
| Audiogram | Bilateral high-frequency sensorineural loss |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; sleeping six hours |
| Gastrointestinal | Positive | Mild constipation |
| Musculoskeletal | Positive | Shoulder pain better; chest wall and back pain persist |
| Psychiatric | Positive | Contamination fears somewhat less; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff **S**
- Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Sertraline 100 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.4 kg; BMI 20.1 kg/m². All vital signs are synthetic.

Right ear threshold at 500 Hz: 20 dB; Left ear threshold at 500 Hz: 20 dB; Right ear threshold at 1000 Hz: 25 dB; Left ear threshold at 1000 Hz: 30 dB (high); Right ear threshold at 1921 Hz: 35 dB (high); Left ear threshold at 1921 Hz: 40 dB (high); Right ear threshold at 4000 Hz: 60 dB (high); Left ear threshold at 4000 Hz: 65 dB (high); PHQ-9: 7; GAD-7: 10; PEG pain scale: 5.7. All results are synthetic.

## Change since baseline

- PHQ-9: 9 at baseline, 7 at this visit **S**
- GAD-7: 12 at baseline, 10 at this visit **S**
- PEG pain scale: 6.7 at baseline, 5.7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 78; weight 73.4 kg, BMI 20.1 |
| Ears | Canals clear; tympanic membranes normal |
| Skin | Hands less cracked |
| Musculoskeletal | Left shoulder elevation 150 degrees |
| Psychiatric | Less tense; no sedation; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Obsessive-compulsive disorder** (F42.2). Y-BOCS 24, down from 28, after four weeks of sertraline 50 mg and four exposure sessions. Sertraline is well tolerated, so the dose goes up. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Sertraline 100 mg daily.
   - Nurse telephone call two weeks after this and every later dose change.
   - Continue weekly exposure and response prevention.
2. **Opioid use disorder on buprenorphine** (F11.20). Stable on 8 mg twice daily with no cravings. The urine test could not be collected because using the clinic bathroom is still beyond his exposure hierarchy. **S**
   - Continue buprenorphine; dispensed two weeks at a time.
   - Urine test at the next visit, as a planned exposure with his therapist's help.
   - More fluids and fiber; a stool softener if needed.
3. **Bilateral sensorineural hearing loss** (H90.3). Thresholds 20 dB at 500 Hz, 25 to 30 dB at 1000 Hz, 35 to 40 dB at 1921 Hz and 60 to 65 dB at 4000 Hz in both ears, with a notch at 4000 Hz: noise-induced hearing loss from years of flying loud aircraft. It makes meetings harder and adds to his isolation. **S**
   - Hearing aids, with a remote microphone for meetings.
   - Hearing protection when flying and in the factory.
4. **Chronic pain after major trauma** (G89.21). PEG 5.7, down from 6.7, on buprenorphine, scheduled acetaminophen and physical therapy. **S**
   - Continue the current plan.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 24; about three hours a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Four of four sessions attended; home practice most days |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Deferred | The two-week tolerability check after sertraline started was not done. No harm: he had no side effects, activation or suicidal thoughts at four weeks. Corrective action: a nurse telephone call two weeks after each dose change, booked today |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | His assistant attended one session; staff still wrap objects in tissue for him |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 7, item 9 scored 0; GAD-7 10 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use; mild constipation; no sedation |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Deferred | Not collected: he could not use the clinic bathroom because of contamination fears. No sign of harm: no other prescriptions on the monitoring report, and he reports no other use. Corrective action: the test is the next step on his exposure hierarchy, with his therapist, at the ten-week visit |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 5.7 |
| Referral | Physical therapy and graded activity | Twice weekly | Completed today | Eight sessions; shoulder elevation 150 degrees |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 73.4 kg, up 1.4 kg; two meals a day |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Baseline normal; next at about six months |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Bilateral high-frequency sensorineural loss with a notch at 4000 Hz |

## Goal progress

- Y-BOCS down by at least 35 percent (response) within six months. In progress; target 1947-10-05. **S**
- Stop codeine and stay on buprenorphine with no use of other opioids. In progress; target 1947-10-05. **S**
- Pain that lets him work and sleep: PEG at or below 4. In progress; target 1947-10-05. **S**
- Regain weight to at least 76 kg with regular meals. In progress; target 1947-10-05. **S**
- Follow conversation in meetings with hearing aids. In progress; target 1947-10-05. **S**
- Staff stop carrying out rituals for him, step by step, by his own plan. In progress; target 1947-10-05. **S**

## Medication changes

- Stopped: Sertraline 50 mg oral tablet, one tablet daily **S**
- Started: Sertraline 100 mg oral tablet, one tablet daily **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association (American Journal of Psychiatry 2007;164(7 Suppl):5-53)
- Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Hearing loss in adults: assessment and management (NG98) (2018), National Institute for Health and Care Excellence
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse telephone call in two weeks. Ten-week review in five weeks, with hearing aid fitting that morning and the urine test as an exposure exercise. Call the clinic or 988 at any time. **S**
- Next scheduled visit 1947-07-13: ten-week review: sertraline to an OCD dose, exposure therapy and his staff's part in it, hearing aids and pain. **S**
